A Prospective, Randomized, Multisite Clinical Evaluation of a Transparent Absorbent Acrylic Dressing and a Hydrocolloid Dressing in the Management of Stage II and Shallow Stage III Pressure Ulcers.

摘要

OBJECTIVE:: To compare clinical performance of a transparent absorbent acrylic dressing (3M Tegaderm Absorbent Clear Acrylic Dressing ]TAAD[; 3M Company, St Paul, MN) and a hydrocolloid dressing (HD ]DuoDERM CGF, ConvaTec, ER Squibb & Sons, Princeton, NJ[) in the management of Stage II and shallow Stage III pressure ulcers. DESIGN:: Prospective, open-label, randomized, comparative, multisite clinical evaluation. Patients were followed up for a maximum of 56 days or until their ulcer healed. At weekly intervals, investigators conducted wound assessments and dressing performance evaluations. SETTING:: Wound care clinics, home care, and long-term care. PATIENTS:: Thirty-five patients received the TAAD, and 37 received the HD. OUTCOME MEASURES:: Dressing performance assessments, patient comfort, dressing wear time, and wound healing were measured. RESULTS:: The majority of investigator assessments favored the TAAD. Considerations given included the ability to center dressings over the ulcer (P = .005), ability to assess the ulcer before (P < .001) and after (P < .001) absorption, barrier properties (P = .039), patient comfort during removal (P < .001), overall patient comfort (P = .048), conformability before (P = .026) and after (P = .001) absorption, ease of removal (P < .001), nonadherence to wound bed (P < .001), residue in the wound (P = .002), residue on periwound skin (P < .001), and odor after absorption (P = .016). Overall satisfaction favored the TAAD (P < .001), and a high value was placed on its transparent feature (P < .001). Mean (SD) wear time for the TAAD was 5.7 (2.55) days compared with 4.7 (2.29) days for the HD (P .086). This 1-day difference in wear time was clinically noticeable by the investigators (P = .035). Wound closure for the 2 dressing groups was nearly identical (P = .9627). CONCLUSIONS:: Performance results favored the TAAD over the HD as standard treatment for Stage II and shallow Stage III pressure ulcers.